Tirzepatide CAS:2023788-19-2
Tirzepatide is an innovative therapeutic peptide that has garnered attention for its multifaceted roles in weight management, glucose control, and metabolic health. This dual-action drug mimics the functions of two key hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Tirzepatide’s ability to target multiple metabolic pathways sets it apart from traditional treatments for type 2 diabetes and obesity.
What is Tirzepatide?
Tirzepatide is a synthetic peptide drug designed to act as a dual agonist for GLP-1 and GIP receptors. These receptors are integral to the regulation of blood glucose levels, insulin secretion, and appetite control. Tirzepatide, marketed under the brand name Mounjaro, was initially developed for managing type 2 diabetes but has demonstrated remarkable efficacy in promoting weight loss and improving metabolic health.
Chemical Composition:
●Molecular Formula: C225H348N48O68
●Molecular Weight: Approximately 4813.5 Da
●CAS Number: 2023788-19-2
Features of Tirzepatide
1.Dual Agonist Action:
●Tirzepatide's ability to activate both GLP-1 and GIP receptors provides a synergistic effect on metabolic pathways, enhancing insulin secretion and reducing appetite.
2.Extended Half-Life:
●Structural modifications allow Tirzepatide to remain active in the body for an extended period, facilitating once-weekly dosing.
3.Synthetic Stability:
●Engineered to resist enzymatic degradation, Tirzepatide offers consistent efficacy over its dosing period.
4.Multi-Targeted Approach:
●Beyond glucose regulation, Tirzepatide impacts lipid metabolism, inflammation, and energy expenditure.
5.FDA-Approved:
●Tirzepatide received FDA approval for type 2 diabetes management, with ongoing studies exploring its broader applications.
Applications of Tirzepatide
1.Medical Applications:
●Type 2 Diabetes: Tirzepatide is primarily prescribed for improving glycemic control in adults with type 2 diabetes. It enhances insulin sensitivity, reduces postprandial glucose spikes, and promotes sustained glucose regulation.
●Obesity Management: Its appetite-suppressing properties and promotion of energy expenditure make it an effective tool for significant weight loss.
●Cardiovascular Health: Tirzepatide's ability to lower triglycerides, improve lipid profiles, and reduce body weight contributes to better cardiovascular outcomes.
2.Off-Label Applications:
●Weight Loss in Non-Diabetics: Tirzepatide is being investigated for use in non-diabetic individuals struggling with obesity.
●Metabolic Syndrome: Its role in reducing visceral fat and improving insulin resistance makes it a potential therapy for metabolic syndrome.
3.Research and Development:
●Studies are exploring its potential in addressing conditions such as non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS).
Benefits of Tirzepatide
1.Improved Glycemic Control:
●Dual agonism enhances insulin secretion and reduces glucose production, providing better control over blood sugar levels.
2.Significant Weight Loss:
●Clinical trials demonstrate that Tirzepatide induces substantial weight loss, with some individuals achieving up to a 20% reduction in body weight.
3.Appetite Regulation:
●By modulating hunger signals in the brain, Tirzepatide reduces calorie intake and prevents overeating.
4.Enhanced Lipid Metabolism:
●The drug improves lipid profiles by reducing triglycerides and LDL cholesterol levels.
5.Reduced Cardiovascular Risk:
●Tirzepatide's ability to lower weight and improve metabolic markers contributes to decreased cardiovascular disease risk.
6.Convenient Dosing:
●Once-weekly administration simplifies treatment regimens, improving patient adherence.
7.Minimal Side Effects:
●Compared to traditional diabetes treatments, Tirzepatide has a favorable safety profile, with most side effects being mild and transient.
Dosage and Administration
1.Dosage:
●Initial Dose: 2.5 mg once weekly for four weeks to assess tolerance.
●Maintenance Dose: Gradual escalation to 5 mg, 10 mg, or 15 mg once weekly, depending on therapeutic goals and individual response.
2.Route of Administration:
●Subcutaneous injection, typically administered in the abdomen, thigh, or upper arm.
3.Timing:
●Consistent weekly administration is recommended, preferably on the same day each week.
4.Adjustments:
●Dosage adjustments may be necessary for individuals experiencing gastrointestinal side effects or insufficient response.
Cycle Recommendations
1.Duration:
●Standard cycles last 12-24 weeks, with adjustments based on individual goals (e.g., weight loss or glycemic control).
2.Starting Phase:
●Begin with the lowest dose to minimize side effects and evaluate tolerance.
3.Maintenance Phase:
●Increase dosage gradually to achieve optimal therapeutic effects.
4.Long-Term Use:
●Tirzepatide may be used as part of a long-term strategy for managing chronic conditions, with regular monitoring by a healthcare provider.
Half-Life and Pharmacokinetics
1.Half-Life:
●Tirzepatide has an extended half-life of approximately 5 days, allowing for once-weekly administration.
2.Duration of Action:
●The prolonged activity ensures consistent therapeutic effects throughout the week.
3.Metabolism and Excretion:
●Metabolized by proteolytic enzymes, with excretion primarily through the renal pathway.
Post-Treatment Considerations (PTC)
1.Transition to Maintenance:
●For individuals using Tirzepatide for weight loss, transitioning to a maintenance diet and exercise program is critical to sustain results.
2.Monitoring:
●Regular follow-ups with a healthcare provider to assess glucose levels, weight, and metabolic markers.
3.Supplementation:
●Incorporating vitamins, minerals, or other supportive supplements may be beneficial, especially for long-term users.
4.Gradual Discontinuation:
●For those discontinuing Tirzepatide, a gradual tapering of the dosage is recommended to prevent abrupt metabolic changes.
Potential Side Effects
1.Common Side Effects:
●Nausea, diarrhea, and vomiting are the most frequently reported issues, especially during the initial dosing phase.
2.Less Common Side Effects:
●Constipation, fatigue, or mild headaches.
3.Serious Adverse Effects:
●Rarely, individuals may experience pancreatitis or severe gastrointestinal discomfort. Immediate medical attention is advised if these occur.
4.Mitigation Strategies:
●Starting with a low dose and gradually increasing can help reduce gastrointestinal side effects.
Storage Guidelines
●Unopened Vials: Store in a refrigerator at 2-8°C (36-46°F).
●Opened Vials: Use within the recommended period, typically 28 days, if kept refrigerated.
●Avoid freezing or exposing to excessive heat or light.
Clinical Data
|
Trade names |
Mounjaro,Zepbound,LY3298176,GIP/GLP-1 RA |
|
CAS |
2023788-19-2 |
|
Molar mass |
4,813.53 |
|
Formula |
C225H348N48O68 |
|
Purity |
Above 98% |
|
Apprarance |
2mg/vial,5mg/vial,10mg/vial,Lyophilized powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
Tirzepatide represents a groundbreaking advancement in the management of type 2 diabetes and obesity. Its dual agonist mechanism targeting GLP-1 and GIP receptors provides comprehensive benefits, including improved glycemic control, significant weight loss, and enhanced metabolic health. With its convenient once-weekly dosing and favorable safety profile, Tirzepatide offers an attractive option for individuals seeking long-term solutions for metabolic disorders. As with any therapeutic agent, proper medical supervision is essential to maximize its benefits and minimize potential risks.
Hot Tags: tirzepatide cas:2023788-19-2, China tirzepatide cas:2023788-19-2 manufacturers, suppliers, factory
